CD47 and prostate cancer: Thus, to test our hypothesis that CD47 deficiency in tumor endothelial cells may enhance angiogenesis, we first assessed the growth and central necrosis in the tumors developed in WT vs. CD47-deficient mice following subcutaneous injection of syngeneic RM1 prostate cancer cells.